ClinicalTrials.gg
RecruitingNCT06241846Updated Aug 27, 2025

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

A Phase 2 interventional study of YL201 for Injection in Metastatic Castration-resistant Prostate Cancer (mCRPC), sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 24 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 541 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 51 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
206th of 435
100 · median 100
Started
2024
with 87 others
Phase 2
84 of 541
51 open now
Primary completion
2027-02
later than 176 of 341 live
Registered
278th of 541
by date

Among the 541 studies in Prostatic Neoplasms with a site in China, this one is the 206th largest by planned enrollment of the 435 interventional ones that give a count, is one of 88 that started in 2024, is one of 84 in phase 2, reaches primary completion later than 176 of the 341 other live ones, and was the 278th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 541 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 541 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who understand relevant information of the study prior to initiation of the study and voluntarily sign and date on the ICF.
  2. Age ≥ 18 years.
  3. Patients should meet the following conditions to be enrolled:

    • or cytologically confirmed prostate cancer. Note: The primary histological classification indicated by should be adenocarcinoma;
    • Meeting the following criteria for clinical diagnosis of mCRPC:

<!-- -->

  1. Subjects who understand relevant information of the study prior to initiation of the study and voluntarily sign and date on the ICF.
  2. Age ≥ 18 years.
  3. Patients should meet the following conditions to be enrolled:

    • Histologically or cytologically confirmed prostate cancer. Note: The primary histological classification indicated by biopsy should be adenocarcinoma;
    • Meeting the following criteria for clinical diagnosis of mCRPC:

    √Testosterone level after castration (a serum testosterone level of \<50 ng/dl or 1.7 nmol/L);

    • Serum prostate specific antigen (PSA) progression (PSA > 1 ng/mL and 2 consecutive increases in PSA with at least a 1-week interval >50% from baseline), or PD by imaging (≥ 2 new bone lesions suggested by a bone scan according to PCWG3 criteria; and/or progression of soft tissue lesions suggested by computed tomography (CT) or nuclear magnetic resonance imaging (MRI) according to v1.1); meeting either or both criteria;
    • Persistent luteinizing hormone-releasing hormone (LHRH) analogue castration (medical castration) or prior bilateral orchiectomy (surgical castration); surgical castration should be performed at least 3 months prior to enrollment, and medical castration is required from at least 3 months prior to the first dose and throughout the study for subjects not yet undertake bilateral orchiectomy; • Patients with progression on or intolerance to at least one prior novel hormone therapy (NHT) (e.g., enzalutamide, abiraterone, darolutamide, apalutamide, or rezvilutamide); • Prior therapy with no more than 2 is allowed; • Patients with known previous prostate adenocarcinoma with a documented BRCA1/2 (germline or somatic) mutation should have received poly ADP ribose polymerase (PARP) inhibitor therapy (if available and tolerated);
  4. Patients with lesions confirmed by CT, MRI, or bone scan imaging within 28 days prior to the first dose.
  5. Patients with archived or fresh tumor tissue samples. Patients who cannot provide tumor samples or cannot provide sufficient samples may be enrolled in this study after considering specific circumstances and discussions with the Sponsor.

    • Fresh tumor tissue samples (formalin-fixed, paraffin-embedded (FFPE) tumor blocks or FFPE sections) should be provided for retrospective detection of B7H3 expression by the central laboratory using the immunohistochemistry [IHC] method; if fresh tumor tissue samples are not available, FFPE tumor blocks previously archived are acceptable, and fresh FFPE sections should be prepared within 2 weeks.
  6. performance status (ECOG PS) score of 0 or 1.
  7. The function of organs and bone marrow meets the requirements within 7 days prior to the first dose, which is defined as follows:

    • (Hb) ≥ 90 g/L (no blood transfusion or erythropoietin treatment within 14 days prior to the first dose);
    • (ANC) ≥ 1.5×109/L (no treatment with granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor within 14 days prior to the first dose);
    • count (PLT) ≥ 100×109/L (no platelet transfusion, thrombopoietin, or interleukin-11 within 14 days prior to the first dose);
    • Total (TBIL) ≤ 1.5× (ULN) in the absence of obvious liver metastasis, or ≤ 3×ULN in the presence of liver metastasis;
    • (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN in the absence of obvious liver metastasis or ≤ 5×ULN in the presence of liver metastasis;
    • Serum albumin (ALB) ≥ 30 g/L;
    • calculated using Cockcroft-Gault formula ≥ 50 mL/min or the creatinine ≤ 1.5×ULN;
    • (APTT) and international normalized ratio (INR) ≤ 1.5×ULN, except for patients who are on anticoagulant therapy. In this case, a stable anticoagulant regimen should be maintained with APTT and INR controlled within the range deemed appropriate by the investigator.
  8. Patients must agree to adopt highly effective measures from screening, throughout the study period, and within at least 6 months after the last dose of the drug.
  9. Expected survival ≥ 6 months.
  10. Be capable of and willing to comply with the visits and procedures stipulated in the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Previously treated with drugs targeting B7H3.
  2. Currently participating in another clinical study, unless it is an observational (non-interventional) clinical study, or the patient is at the follow-up period of an interventional study.
  3. Previously treated with topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors.
  4. The of the previous anti-tumor therapy is considered insufficient.
  5. Patients received major surgery.
  6. Prior treatment with bone marrow transplantation or solid organ transplantation.
  7. Prior treatment with for more than 28 consecutive days within 28 days prior to the first dose of the drug.
  8. Patients received any within 4 weeks prior to the first dose of the investigational drug, or plan to receive live vaccine during the study period.
  9. Have pathological long bone fracture, or the risk of pathological long bone fracture.
  10. Have meningeal or cancerous meningitis.
  11. Have uncontrolled bladder outlet obstruction or urinary incontinence.
  12. Have or spinal cord compression.
  13. Patients with uncontrolled or cardiovascular diseases.
  14. Clinically significant complicated pulmonary disorders.
  15. Diagnosed with Gilbert's syndrome.
  16. Accompanying uncontrolled effusion in the third space requiring repeated drainage.
  17. Medical history of gastrointestinal perforation and/or fistula within 6 months prior to the first dose, or active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal diseases that may cause hemorrhage or perforation in the opinion of the investigator.
  18. Active serious infection (National Cancer Institute [NCI CTCAE] ≥ 3) within 4 weeks prior to the first dose.
  19. Known (HIV) infection.
  20. Active virus (HBV) or virus (HCV) infection.
  21. Diagnosed with the other that may change the expected survival or affect the response evaluation.
  22. Unresolved toxicity of previous anti-tumor therapy.
  23. History of severe to inactive ingredients in the drug substance and drug product or other monoclonal antibodies.
  24. Have any diseases, medical conditions, organ system dysfunction, or social conditions that may interfere with the subject ability to sign the ICF, adversely affect the subject ability to cooperate and participate in the study, or affect the interpretation of study results, including but not limited to mental illness or substance/alcohol abuse, in the opinion of the investigator.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Part 1

    To evaluate the safety and efficacy of YL201 in patients with mCRPC and to determine the recommended dose of YL201 for the pivotal clinical study (n ≈ 60); Cohort 1: YL201 2.0 mg/kg iv Q3W ; Cohort 2: YL201 1.6 mg/kg iv Q3W; Cohort 3: YL201 2.4 mg/kg iv Q3W; Cohort 4: YL201 1.2 mg/kg iv D1, D8 Q3W; Cohort 5: YL201 1.0 mg/kg iv D1, D8, Q3W;

    Drug: YL201 for Injection

  • Experimental
    Part2

    To evaluate the safety and efficacy of YL201 in patients with mCRPC and to determine the recommended dose of YL201 for the pivotal clinical study (n ≈ 40); Recommended dose and method of administration

    Drug: YL201 for Injection

Interventions

  • Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) by RECIST1.1 and PCWG3 criteria per investigators' review

    defined as percentage of participants with confirmed best overall response of confirmed complete response (CR) or partial response (PR) to treatment

    Time frame: Approximately within 36 months

  2. Radiographic progression free survival (rPFS), and rPFS rate at 3/6 months by RECIST1.1 and PCWG3 criteria per investigators' review

    defined as the time from the date of first administration to first documented progressive disease (PD) per RECIST1.1 and PCWG3 or death from any cause, whichever occurs first.

    Time frame: Approximately within 36 months

  3. Recommended dose of YL201 for the pivotal clinical trial.

    Time frame: Approximately within 36 months

Secondary outcomes

  1. disease control Rate (DCR) by RECIST1.1 and PCWG3 criteria per investigators' review

    Disease control rate

    Time frame: Approximately within 36 months

  2. To evaluate DoR by RECIST1.1 and PCWG3 criteria per investigators' review of YL201 in the treatment of mCRPC

    Duration of rasponse

    Time frame: Approximately within 36 months

  3. To evaluate TTR of YL201 in the treatment of mCRPC

    Time to Objective response

    Time frame: Approximately within 36 months

  4. To evaluate DpR of YL201 in the treatment of mCRPC

    deepness of response

    Time frame: Approximately within 36 months

  5. To evaluate PSA50 response rate and PSA50 response rate at 12 weeks of YL201 in the treatment of mCRPC

    PSA50 response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3 weeks after the first documented reduction in PSA of ≥ 50%.

    Time frame: Approximately within 36 months

  6. To evaluate TTPR of YL201 in the treatment of mCRPC

    time to PSA response

    Time frame: Approximately within 36 months

  7. To evaluate PDoR of YL201 in the treatment of mCRPC

    PSA duration of response

    Time frame: Approximately within 36 months

  8. To evaluate PDpR of YL201 in the treatment of mCRPC

    PSA deepness of response

    Time frame: Approximately within 36 months

  9. To evaluate TTPP of YL201 in the treatment of mCRPC

    time to PSA progression

    Time frame: Approximately within 36 months

  10. To evaluate TFST of YL201 in the treatment of mCRPC

    time to first subsequent therapy

    Time frame: Approximately within 36 months

  11. To evaluate rPFS of YL201 in the treatment of mCRPC

    Radiographic Progression Free Survival

    Time frame: Approximately within 36 months

  12. To evaluate OS of YL201 in the treatment of mCRPC

    overall survival

    Time frame: Approximately within 36 months

  13. To evaluate time to first symptomatic skeletal event of YL201 in the treatment of mCRPC

    assessed by investigator according to RECIST v1.1 and PCWG3 criteria

    Time frame: Approximately within 36 months

  14. Expression of B7H3 in tumor tissue at baseline and the relationship with the efficacy of YL201.

    Time frame: Approximately within 36 months

  15. Number of participants with AEs, SAEs, and SAEs leading to study treatment interruption or discontinuation.

    adverse event, serious adverse event

    Time frame: Approximately within 36 months

  16. To evaluate the AUC of YL201

    the area under curve: AUC is the total amount of YL201 in bloodstream after drug administration

    Time frame: Approximately within 36 months

  17. To evaluate the Cmax of YL201

    Maximum concentration: The highest measured concentration of YL201 in the bloodstream.

    Time frame: Approximately within 36 months

  18. To evaluate the Ctrough of YL201

    trough concentration

    Time frame: Approximately within 36 months

  19. To evaluate the CL of YL201

    Clearance: defined as the amount of drug removed from the bloodstream by the body per unit of time

    Time frame: Approximately within 36 months

  20. To evaluate the Vd of YL201

    volume of distribution

    Time frame: Approximately within 36 months

  21. To evaluate the T1/2 of YL201

    Terminal half-life: defined as the time it takes for the concentration of the drug in plasma or serum to be reduced by 50%

    Time frame: Approximately within 36 months

  22. To evaluate the E-R relationship of YL201

    exposure-response

    Time frame: Approximately within 36 months

  23. To evaluate the immunogenicity of YL201

    Time frame: Approximately within 36 months

07

Study locations

2 of 24 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 36 months is close to that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2024
First posted
Feb 5, 2024
StartActual
Feb 22, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2029
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06241846
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Feb 22, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2029 (estimated)
Last update
Aug 27, 2025

Study contacts

Sasha Stann
Contact
sasha@medilinkthera.com
06172408494
Steve Chin, Ph.D.
Contact
info@medilinkthera.com
06178719455

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tambotatug pelitecan

Start the discussion